Gedea Biotech

Gedea Biotech secures 1.3 MEuros (14 MSEK) to advance its antibiotic-free vaginal infection treatment pHyph

Gedea Biotech today announced that it has raised 1.3 MEuros (14 MSEK) for additional development activities of their product pHyph for antibiotic free treatment of… Read More

Gedea Biotech initiates EpHect Clinical Trial for Antibiotic-free Treatment of Women with Vulvo Vaginal Candidiasis

  ·        Up to 75% of all women are affected by vaginal infection in their lifes ·        Self-diagnoses leads often to unnecessary and inappropriate treatment use ·        This… Read More

Gedea Biotech obtains US-patent covering pHyph for antibiotic-free treatment and prevention of bacterial vaginosis

·        Important expansion of patent estate in the largest market for vaginal bacterial infections ·        pHyph has shown superior safety profile, a cure rate in line with… Read More

Gedea Biotech appoints Anna-Karin Areskog as QA Director and receives ISO13485 certification

Gedea Biotech announces today that Anna-Karin Areskog has been appointed QA Director and that their ISO13485* re-certification has been approved. Both the announcement and the… Read More

Gedea Biotech tilldelas 3 MSEK från SWElife och MedTech4Health för banbrytande, antibiotikafri behandling inom kvinnohälsa

Positiv påverkan på mikrobiomet kan vara nyckeln till att förhindra återfall av vulvovaginal infektion Gedea Biotech meddelar idag att man har beviljats 3 miljoner kronor… Read More